These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

195 related articles for article (PubMed ID: 15213665)

  • 1. [Anti-TNF agents in inflammatory bowel disease: indications and management].
    Cocq P; Yazdanpannah Y; Mesnard B; Colombel JF
    Gastroenterol Clin Biol; 2004 May; 28(5 Suppl):D61-9. PubMed ID: 15213665
    [No Abstract]   [Full Text] [Related]  

  • 2. CDP 571. Anti-TNF monoclonal antibody, BAY 103356.
    Drugs R D; 1999 Mar; 1(3):253-5. PubMed ID: 10566038
    [No Abstract]   [Full Text] [Related]  

  • 3. Safety of infliximab and other biologic agents in the inflammatory bowel diseases.
    Reddy JG; Loftus EV
    Gastroenterol Clin North Am; 2006 Dec; 35(4):837-55. PubMed ID: 17129816
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Therapeutic potential of infliximab in inflammatory bowel disease.
    Hurd LB; Lichtenstein GR
    Gastroenterol Nurs; 1999; 22(5):199-208. PubMed ID: 10776108
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of biologics in inflammatory bowel disease patients with cirrhosis.
    Dhere T
    Inflamm Bowel Dis; 2011 Feb; 17(2):E15-6. PubMed ID: 20878757
    [No Abstract]   [Full Text] [Related]  

  • 6. Non-response to infliximab may be due to innate neutralizing anti-tumour necrosis factor-alpha antibodies.
    Ebert EC; Das KM; Mehta V; Rezac C
    Clin Exp Immunol; 2008 Dec; 154(3):325-31. PubMed ID: 18826498
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Infliximab in ulcerative colitis.
    Aberra FN; Lichtenstein GR
    Gastroenterol Clin North Am; 2006 Dec; 35(4):821-36. PubMed ID: 17129815
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Application of TNF-alpha blocker concentration assays in the treatment of inflammatory bowel diseases].
    Sipponen T; Kolho KL
    Duodecim; 2013; 129(5):499-505. PubMed ID: 23520893
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Long-term safety of Infliximab for the treatment of inflammatory bowel disease: does blocking TNFalpha reduce colitis-associated colorectal carcinogenesis?
    Biancone L; Petruzziello C; Calabrese E; Zorzi F; Naccarato P; Onali S; Pallone F
    Gut; 2009 Dec; 58(12):1703. PubMed ID: 19923350
    [No Abstract]   [Full Text] [Related]  

  • 10. [New inflammatory bowel disease drugs targeting the inflammatory cascade].
    Desreumaux P
    Gastroenterol Clin Biol; 2001 Apr; 25(4 Suppl):B72-8. PubMed ID: 11449147
    [No Abstract]   [Full Text] [Related]  

  • 11. Understanding the complications of anti-tumor necrosis factor therapy in East Asian patients with inflammatory bowel disease.
    Cheon JH
    J Gastroenterol Hepatol; 2017 Apr; 32(4):769-777. PubMed ID: 27723166
    [TBL] [Abstract][Full Text] [Related]  

  • 12. The immunogenicity of biosimilar infliximab: can we extrapolate the data across indications?
    Ben-Horin S; Heap GA; Ahmad T; Kim H; Kwon T; Chowers Y
    Expert Rev Gastroenterol Hepatol; 2015; 9 Suppl 1():27-34. PubMed ID: 26395532
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Anti-TNF therapy for Crohn's disease: a perspective (infliximab is not the drug we have been waiting for).
    Shanahan F
    Inflamm Bowel Dis; 2000 May; 6(2):137-9. PubMed ID: 10833074
    [No Abstract]   [Full Text] [Related]  

  • 14. The Era of Anti-Tumor Necrosis Factor Is Over. What Do We Know, What Don't We Know, and What Do We Yearn to Know?
    Dwadasi S; Israel A; Rubin DT
    Gastrointest Endosc Clin N Am; 2019 Jul; 29(3):405-419. PubMed ID: 31078244
    [No Abstract]   [Full Text] [Related]  

  • 15. [Biologics in current therapy for inflammatory bowel disease].
    Hisamatsu T; Hibi T
    Nihon Rinsho Meneki Gakkai Kaishi; 2009 Jun; 32(3):168-79. PubMed ID: 19564713
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A Review on the Use of Anti-TNF in Children and Adolescents with Inflammatory Bowel Disease.
    Aardoom MA; Veereman G; de Ridder L
    Int J Mol Sci; 2019 May; 20(10):. PubMed ID: 31126015
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Effects of tumor necrosis factor alpha inhibition with infliximab on lipid levels and insulin resistance in patients with inflammatory bowel disease.
    Koutroubakis IE; Oustamanolakis P; Malliaraki N; Karmiris K; Chalkiadakis I; Ganotakis E; Karkavitsas N; Kouroumalis EA
    Eur J Gastroenterol Hepatol; 2009 Mar; 21(3):283-8. PubMed ID: 19279474
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Clinical and scientific aspects related to biosimilars in inflammatory bowel diseases (IBD): position document of the Belgian IBD Research & Development Group (BIRD).
    Vermeire S; Louis E; Dewit O; Franchimont D; Moreels T; Ferrante M; Rahier JF; Van Hootegem P; De Vos M; Mana F; Baert F;
    Acta Gastroenterol Belg; 2015; 78(1):26-9. PubMed ID: 26118575
    [No Abstract]   [Full Text] [Related]  

  • 19. [Perspectives in inflammatory bowel diseases treatment].
    Jalocha L; Wojtuń S; Dyrla P; Błaszak A; Wojtkowiak M; Zyśko B; Stelmaszuk T; Gil J
    Pol Merkur Lekarski; 2009 May; 26(155):556-8. PubMed ID: 19606725
    [TBL] [Abstract][Full Text] [Related]  

  • 20. [Chronic inflammatory bowel disease - new therapies: tumor necrosis factor-antibodies and cytokines].
    Stange EF
    Z Gastroenterol; 2002 Apr; 40 Suppl 1():S90-S1. PubMed ID: 11930299
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.